- Product Details
- Description
- Additional information
- More Offers
Description
Background Information:
AHU-377 (Sacubitril) is a prodrug which is activated in vivo by hydrolytic enzyme esterases to form an active compound LBQ657 that selectively and potently inhibits the enzyme Neprilysin with Ki at low nM. Neprilysin is a protease responsible for the degradation of atrial and brain natriuretic peptides. Inhibition of the enzyme prevents the degradation of natriuretic peptides and activates cGMP signaling pathways that regulate volume and blood pressure. AHU-377 (Sacubitril) is an investigational antihypertensive drug being studied for use in combination with Valsartan (molar ratio: 1:1) (Our Prod No. CT-VALS). The combination drug, known as LCZ696, is in clinical trials for the treatment of heart failure.
Reference:
1. L. G. Hegde, et al., Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension, BMC Pharmacol. 2011; 11(Suppl 1): P33.
2. A. A. Voors, et al., The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug. 22(8):1041-7.* Confirmed precisely by a perfect Quantitative Elemental Analysis.
APIM050357: AHU-377 (SACUBITRIL)
CAS No.: 149709-62-6.
Molecular Formula: C24H29NO5 ? C4H11NO3.
Molecular Weight: 532.6.
Purity: >99% chem and stereomeric purity.
QC: HPLC, NMR and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Additional information
Ship from Country | USA |
---|---|
Size | 10 mg, 5 mg, 50 mg |